Digital Transformation in Biopharma – A Review

Digital Transformation in Biopharma – A Review

Over the last three decades, the cost of drug R&D has increased by ten-fold. As a result, biopharmaceutical companies are looking for new ways to approach modern day drug hunting. The ongoing COVID-19 pandemic has been a catalyst for many organisations to embrace the opportunities that digitisation brings.

D4 Pharma’s report ‘Digital Transformation in Biopharma – A Review’ provides unique insights and lessons learned from biopharma in this digital revolution. This report highlights how digital strategies can improve R&D, and how the companies that are adopting these strategies are increasing efficiencies within their organisations and dealing with emerging challenges.

What’s inside?

• Chapter 1: Why be a digital pharma player? A discussion of the motivations behind digitisation at scale and why it is important to keep up.
   
• Chapter 2: Increasing velocity in preclinical R&D. In this chapter, we focus on how preclinical R&D represents a huge opportunity to improve productivity challenges.
   
• Chapter 3: Automation in drug discovery. This chapter covers ways in which modern automated technology can transform the R&D lab into the lab of the future – from wet lab pipetting techniques to LIMS.
   
• Chapter 4: Harnessing AI/ML for R&D. AI and ML are transforming the industry. In this chapter, the role of AI and ML in drug discovery are explored as well as the challenges to its widespread adoption.
   
• Chapter 5: Digitising clinical trials. Clinical trials are changing. This chapter will look at how digitisation is impacting clinical trials – from data collected via wearables to increasing patient engagement through communication channels.
   
• Chapter 6: Harnessing data and analytics at scale. An exploration of the various ways pharma are looking to transform the way they analyse data.
   
• Chapter 7: Grand challenges to adoption. Despite the promise of digitisation, several challenges remain. This chapter highlights the challenges to adoption and these are being addressed by pharma now.
   
• Chapter 8: The path towards digital pharma R&D. A summary of the digital path ahead and what this means for pharma R&D.

Contributors:

• Cindy Novak, LCS, Lab operations, Systems Manager, Bristol Myers Squibb
   
• Sonia Houston Pichardo, Digital Trials lead Europe, Boehringer Ingelheim
   
• Sreetama Basu, Data Scientist, Merck
   
• Casandra Mangroo, Vice President of Science, BenchSci